Lactate dehydrogenase predicts combined progression‐free survival after sequential therapy with abiraterone and enzalutamide for patients with castration‐resistant prostate cancer

Abstract

The results of this study suggested the A-E sequence had longer combined PSA and total PSA-PFS compared to the E-A sequence in patients with CRPC. LDH values in sequential therapy may serve as a predictor of longer combined PFS.

Current treatment strategies for advanced prostate cancer

“…There have been a number of studies reporting sequential use of ASIs, namely enzalutamide followed by abiraterone [28][29][30][31][32] and abiraterone followed by enzalutamide (Table 3). [31][32][33][34][35][36][37][38] Data seem to show a blunted effect of each after the use of the other, suggesting cross-resistance.…”

“…[31][32][33][34][35][36][37][38] Data seem to show a blunted effect of each after the use of the other, suggesting cross-resistance. It remains unclear which patients benefit from one agent as the first agent compared with the other.…”

Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

“…Information on the included studies is presented in Table 1. All five studies were retrospective case-control studies [16][17][18][19][20].…”

“…Three were conducted in Japan [17,18,20], one in the United States [19], and one in Japan and the United States [16]. Patients enrolled in the Maughan et al study were also participants in the Terada et al study [16,19].…”

“…All trials enrolled patients diagnosed with CRPC who had undergone ARAT treatment according to either ABI-ENZA or ENZA-ABI. In addition, the studies of Maughan et al and Mori et al included both chemo-naïve and post-chemotherapy CRPC patients [17,19]. The other studies were performed only in chemo-naïve CRPC patients [16,18,20].…”